The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, growing at a CAGR of 15.9%. Factors such as the increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of this market.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly